NDA 018664 · Anbex
Iosat
Potassium Iodide · Oral
Last checked: Nov 20, 2026Latest source record: Dec 20, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Oct 14, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
549
97 Phase 3, 39 recruiting
FAERS reports
1,413
1,272 serious, 385 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 3, 2025.
Uses Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials. INDICATIONS IOSAT™ (Potassium Iodide tablets, USP) is a thyroid blocking medicine that is used in a nuclear radiation emergency only.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 1982 Original approval
2 products under this application
- IOSAT · POTASSIUM IODIDE 65MG · TABLET, ORAL · Over-the-counter
- IOSAT · POTASSIUM IODIDE 130MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Iodide" as an intervention, any sponsor and status, largest first.
- Mupirocin-Iodophor ICU Decolonization Swap Out TrialPivotal-lookingCompleted
Harvard Pilgrim Health CareAcademic, hospital or other
NCT03140423 · 353,323 participants · Start May 1, 2017 · Primary completion Nov 6, 2023
Drug: Arm 1. Routine Care (Mupirocin/CHG); Arm 2. Iodophor/CHG Decolonization · For: Staphylococcus Aureus
Sites: Riverside, California; San Jose, California; Thousand Oaks, California · 137 sites in all
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Infection Prophylaxis in Total Joint ReplacementPivotal-lookingRecruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06126614 · 21,006 participants (planned) · Start May 7, 2024 · Primary completion Nov 2028
Drug: Chlorhexidine Gluconate; Vancomycin Hydrochloride · For: Periprosthetic Joint Infection
Sites: Hamilton, Canada
- Project PROTECT: Protecting Nursing Homes From Infections and HospitalizationPivotal-lookingCompleted
University of California, IrvineAcademic, hospital or other
NCT03118232 · 13,952 participants · Start Apr 3, 2017 · Primary completion Oct 10, 2023
Drug: Chlorhexidine gluconate (CHG); Iodophor (10% povidone-iodine) · For: Hospitalization; Infection
Sites: Anaheim, California; Bellflower, California; Capistrano Beach, California · 28 sites in all
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06383390 · 10,000 participants (planned) · Start Apr 30, 2024 · Primary completion Feb 2029
Drug: Retatrutide; Placebo · For: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)
Sites: Alabaster, Alabama; Birmingham, Alabama; Daphne, Alabama · 742 sites in all
- Pre-operative Alcohol Skin Solutions in Fractured ExtremitiesPivotal-lookingCompleted
University of Maryland, BaltimoreAcademic, hospital or other
NCT03523962 · 8,485 participants · Start Aug 21, 2018 · Primary completion Mar 15, 2023
Drug: DuraPrep; ChloraPrep · For: Surgical Site Infection; Unplanned Fracture-Related Reoperation; Open Appendicular Fracture and 2 more
Sites: Irvine, California; Los Angeles, California; San Jose, California · 27 sites in all
- FALCON Trial Testing Measures to Reduce Surgical Site InfectionPivotal-lookingCompleted
University of BirminghamAcademic, hospital or other
NCT03700749 · 5,788 participants · Start Nov 29, 2018 · Primary completion Sep 7, 2020
Drug: 2% chlorhexidine + non-coated suture; 2% chlorhexidine + coated suture and 2 more · For: Abdominal Surgery; Surgical Site Infection
Sites: Cotonou, Benin; Tamale, Ghana; Ludhiana, India · 7 sites in all
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19Pivotal-lookingCompleted
National University Hospital, SingaporeAcademic, hospital or other
NCT04446104 · 4,257 participants · Start May 13, 2020 · Primary completion Aug 31, 2020
Drug: Hydroxychloroquine Sulfate Tablets; Ivermectin 3mg Tab and 2 more · For: Covid-19
Sites: Singapore, Singapore
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea276
- haemorrhagic stroke257
- sepsis257
- dyspnoea256
- fatigue250
- fall247
- headache243
- tachycardia242
- cardio-respiratory arrest241
- insomnia240
- dizziness239
- cough238
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 9 |
| 2007 | 14 |
| 2008 | 14 |
| 2009 | 16 |
| 2010 | 13 |
| 2011 | 14 |
| 2012 | 12 |
| 2013 | 26 |
| 2014 | 28 |
| 2015 | 38 |
| 2016 | 48 |
| 2017 | 50 |
| 2018 | 62 |
| 2019 | 76 |
| 2020 | 104 |
| 2021 | 91 |
| 2022 | 186 |
| 2023 | 162 |
| 2024 | 263 |
| 2025 | 133 |
| 2026 | 46 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Iontophoresis in the treatment of pain].
Schuhfried O, Fialka-Moser V · Wien Med Wochenschr 1995 · Clinical Trial, Comparative Study
- Guaiphenesin and iodide.
· Drug Ther Bull 1985 · Clinical Trial
- Blood Eosinophils Subtypes and Their Survivability in Asthma Patients.
Januskevicius A, Jurkeviciute E, Janulaityte I, et al. · Cells 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
- Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
Cook J, Peng KW, Witzig TE, et al. · Blood Adv 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
- Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N, Upreti D, Zhou Y, et al. · Leukemia 2020 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Thyroidectomy: is Lugol's iodine necessary?
Coyle PJ, Mitchell JE · Ann R Coll Surg Engl 1982 · Clinical Trial, Randomized Controlled Trial
Sponsor: Anbex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.